Clinical Trial: NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-05-28 |
Study Overview
Brief Summary
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may shrink or stabilize cancer in patients undergoing treatment for HIV.
Official Title
Conditions
Intervention / Treatment
- Procedure: Biospecimen Collection
- Drug: Cabozantinib S-malate
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Biological: Nivolumab
Other Study ID Numbers
- NCI-2020-05956
- NCI-2020-05956
- 2020-12258
- 10387
- 10387
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-05-28 |
Study Overview
Brief Summary
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may shrink or stabilize cancer in patients undergoing treatment for HIV.
Official Title
Conditions
Intervention / Treatment
- Procedure: Biospecimen Collection
- Drug: Cabozantinib S-malate
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Biological: Nivolumab
Other Study ID Numbers
- NCI-2020-05956
- NCI-2020-05956
- 2020-12258
- 10387
- 10387